An interventional study of Overdose prevention resources and Overdose prevention education in Accidental Overdose of Opiate, sponsored by University of Alabama at Birmingham. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Opioid-Related Disorders by University of Alabama at Birmingham — 5 open to participants now, 5 under way, none of them phase 3. Opioid-Related Disorders · University of Alabama at Birmingham.
Among the 10 studies in Opioid-Related Disorders by University of Alabama at Birmingham, this one is the only one that started in 2027, is one of 4 with no phase, and was the 9th registered.
1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.
Browse Opioid-Related Disorders studies →5 of the 10 studies in Opioid-Related Disorders by University of Alabama at Birmingham are open now, in 1 country. Recruiting first, the newest first:
University of Alabama at Birmingham · Sites in United States
Ages 19+
University of Alabama at Birmingham · Sites in United States
Ages 18+
University of Alabama at Birmingham · Sites in United States
Ages 18–60 · Healthy volunteers
University of Alabama at Birmingham · Sites in United States
Ages 18–80 · Healthy volunteers
By country, each count listing its studies:
Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 63 across 1,170 interventional studies indexed under Opioid-Related Disorders.
Median enrollment 44 across the 9 interventional studies, 200 across the 1 observational. Of the 3 that completed or were terminated, 3 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Alabama at Birmingham is the lead sponsor of 1,422 studies on the registry; 277 are open to participants now.
Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.
1 of the studies in Opioid-Related Disorders by University of Alabama at Birmingham that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07128485University of Alabama at BirminghamRemote Intervention to Prevent Overdose | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Opioid-Related Disorders by University of Alabama at Birmingham, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This Type 1 hybrid effectiveness-implementation randomized controlled trial, A Remote Intervention to Prevent Overdose among People who Use Stimulants and/or Opioids, aims to address the United States opioid crisis driven by fentanyl and other synthetic opioids by reducing overdose rates. It is supported by and included in the HEAL Initiative. This study would be the first national, fully remote trial to assess the impact of remote education on overdose outcomes, using a novel 2x2 design crossing remote education with remote access support. This research will inform scalability around remote education programs to address the nation's opioid overdose crisis.
This Type 1 hybrid effectiveness-implementation randomized controlled trial aims to address the United States overdose crisis driven by fentanyl and other synthetic opioids. Extant studies of overdose prevention programs are limited to single cities or regions and enroll from brick-and-mortar sites, with no national, fully remote RCTs to date, and it remains unknown whether education alone drives behavior change independent of access. This study will be the first national, fully remote trial to isolate the independent impact of remote education on overdose outcomes. This project adapts our opioid overdose education and naloxone distribution intervention using a human-centered design approach, leveraging community partnerships to co-create a fully remote intervention focused on overdose prevention strategies. Access to overdose prevention resources will be made available to participants independent of this award through referral to community partners. We will use a 2×2 design crossing remote education with remote access support, isolating the individual and combined effects of these two components. The R61 phase focuses on adapting and piloting the interventions with 100 participants, assessing feasibility, acceptability, and appropriateness. The R33 phase implements a fully powered trial to compare overdose outcomes (fatal and non-fatal) among 2,952 participants randomized to four arms: education plus access support, education only, access support only, and referral only (control). All groups will receive a resource list for overdose prevention tools. The secondary outcome is knowledge of how to use the resources correctly; exploratory outcomes include protective behavioral strategies to reduce overdose risk and utilization of substance use services and treatment. The study incorporates ecological momentary assessment to elucidate daily contextual factors influencing resource use, and a cost-effectiveness analysis to identify the most cost efficient approach. Findings will directly inform scalable, low-barrier models capable of reaching rural and underserved populations not currently engaged in substance use services.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This arm receives both overdose prevention education and access to overdose prevention resources.
Other: Overdose prevention resources · Behavioral: Overdose prevention education
The Education only arm receives overdose prevention education.
Behavioral: Overdose prevention education
This arm receives access to overdose prevention resources.
Other: Overdose prevention resources
The referral only arm receives a resource list for obtaining naloxone and other overdose prevention resources on their own.
Overdose prevention resources (e.g., naloxone) are resources used to prevent drug overdose.
Developed in the R61 phase, the educational intervention will provide participants with knowledge about how prevent drug overdose.
Overdose
Includes both self-reported non-fatal overdose and fatal overdose
Time frame: Baseline, 1 month, 3 months, 6 months
Overdose prevention knowledge
Self-reported knowledge of how and when to use overdose prevention tools correctly, based on the education intervention developed in R61 phase
Time frame: Baseline, 1 month, 3 months, 6 months
Plan to share: Yes — The study team will share de-identified individual participant data (IPD) underlying the results reported in publications arising from this trial. Shared IPD will include participant-level data on demographics, overdose prevention knowledge and self-efficacy, perceived overdose risk, overdose history, substance use service engagement, protective behavior strategies, screening survey responses, and ecological momentary assessment (EMA) data. All shared datasets will be stripped of direct identifiers and other information that could reasonably be used to identify participants. Aggregate recruitment and retention data will also be made publicly available. Data sharing will comply with applicable federal regulations, institutional policies, and participant confidentiality protections.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: De-identified individual participant data and supporting documentation will be made available no later than one year after publication of the primary study outcomes, or earlier if required by applicable federal data-sharing policies. Data will remain available for a minimum of ten years following release. Supporting materials, including the final study protocol, statistical analysis plan, analytic code, and data dictionary, will be made available at the time of data release.
Access criteria: Access to de-identified individual participant data will be restricted to qualified investigators conducting scientifically sound research.
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Nov 2027, 10 months later.
Of 465 non-industry interventional studies with no phase under Opioid-Related Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's planned 10 months is below that.
Counting every sponsor, half of 496 studies reached it within 29 months; a quarter within 13 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Alabama at Birmingham →